Clinical approaches to minimize rash associated with EGFR inhibitors.
OBJECTIVE
To present a systematic approach for managing the skin rash associated with epidermal growth factor receptor (EGFR)-targeted therapies.


METHODS
Clinical research literature, published abstracts, and clinical experience. The approach presented in this article is based on a combination of clinical experience and consultations with dermatologists, oncologists, and pharmacists familiar with EGFR inhibitor-associated rash.


RESULTS
A proactive approach that includes patient education and the use of a grade-based treatment algorithm. The goal of the approach is to minimize the effects of the rash on patients' quality of life and the course of cancer treatment.


CONCLUSIONS
Using the approach described in this article to treat the rash associated with the use of EGFR inhibitors, nurses can lessen patient discomfort and help ensure that patients will continue cancer treatment for as long as necessary.


CONCLUSIONS
The approach described in this article should help nurses to recognize, grade, and treat the skin rash associated with EGFR inhibitors.
Oishi
Karen
K
University of Texas M.D. Anderson Cancer Center, Houston, USA. koishi@mdanderson.org
D000465:Algorithms; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology / Q000451:nursing / Q000473:pathology / Q000628:therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009730:Nursing Assessment; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*
D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors